Updates are available Correction dated 2025-12-11
Click to view Correction: https://doi.org/10.1007/s00467-025-07087-4
-
Authors
Lo Re, Claudia
Kim, Jin-Ju
Fornoni, Alessia
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK136679)
National Institute of Diabetes and Digestive and Kidney Diseases (R56DK104753)
National Institute of Diabetes and Digestive and Kidney Diseases (UE5DK137308)
National Institute of Diabetes and Digestive and Kidney Diseases (U54DK083912)
National Institute of Diabetes and Digestive and Kidney Diseases (U24DK100845)
National Institute of Diabetes and Digestive and Kidney Diseases (U01DK116101)
National Institute of Diabetes and Digestive and Kidney Diseases (K01DK127002)
Miami Clinical and Translational Science Institute, University of Miami (UM1TR004556)
- License Information
-
More Information
Article History
Received: 24 June 2025
Revised: 24 September 2025
Accepted: 17 October 2025
First Online: 16 November 2025
Change Date: 11 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00467-025-07087-4
Declarations
:
: A.F. is inventor of pending or issued patents (US10, 183, 038, US 10,052, 345) aimed at diagnosing or treating proteinuric kidney diseases. She stands to gain royalties from her future commercialization of these patents. A.F. is Vice-President of L&F Health LLC and is a consultant for ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin from L&F Research for the treatment of kidney disease. A.F holds equities in River 3 Renal Corporation. C.L.R. and J.J.K. have no conflicts of interest to disclose. Although some experimental agents discussed (e.g., HPβCD, R3R01) are linked to these disclosures, the studies cited were performed independently, and their findings have not been influenced by these relationships.
